This spring

CJC-1295 left FDA compounding purgatory in April — and today the oral comment window closes

Today, June 30, 2026, is the last day to submit oral presentation requests for the FDA's Pharmacy Compounding Advisory Committee meeting scheduled for July 23–24 at the White Oak Campus in Silver Spring. CJC-1295 is not on that agenda. That absence is the story. Unlike BPC-157, TB-500, semax, MOTS-c, and epitalon — all on the PCAC docket for formal safety and access review — CJC-1295 was already moved off the FDA's Category 2 restricted compounding list in April 2026, weeks before the committee's formal review cycle began. The reclassification was part of a broader HHS-directed announcement by Secretary RFK Jr on February 27, 2026: approximately 14 of 19 peptides on the Category 2 prohibition list would return to Category 1 status. As [Pharmacy Times covered in June 2026](https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means), CJC-1295 was specifically named in the reclassification alongside ipamorelin — the secretagogue it is almost always paired with in clinical and optimization contexts. Category 1 means a licensed 503A compounding pharmacy can legally prepare the compound for a specific patient with a valid prescription. It is not FDA approval. The optimization community has spent months processing the return. The clinical evidence is what it was before the ban began.

The actual mechanism

a GHRH analog with a DAC modification — longer half-life, same downstream axis

Native growth hormone releasing hormone is a 44-amino-acid peptide produced by the hypothalamus that signals through pituitary GHRH receptors to trigger pulses of growth hormone. The problem is pharmacokinetics: endogenous GHRH is metabolized in minutes. CJC-1295 — formally designated DAC-GRF, or modified GRF(1-29) with a Drug Affinity Complex — addresses that limitation by covalently binding to serum albumin, the most abundant protein in blood. Albumin binding dramatically extends the peptide's residence time from minutes to days. The downstream biology runs through the normal GH/IGF-1 axis: pituitary growth hormone release, followed by IGF-1 production primarily in the liver, followed by the cellular signaling that IGF-1 mediates in skeletal muscle, adipose tissue, and bone. The mechanism makes pharmacological sense — this is the same axis that governs growth and repair biology throughout human development. The critical question the mechanism does not answer is whether amplifying that axis in healthy adults produces the specific outcomes that define the optimization case: lean mass accrual, fat reduction, improved recovery, better sleep quality, anti-aging markers. The axis is real. Moving it is not the same as moving those outcomes. The Drug Affinity Complex modification is an engineering solution to a genuine pharmacokinetic problem. The rest is still a hypothesis about what happens when you run that experiment in a healthy person over time.

The stack story

paired with ipamorelin for a decade, the protocol runs on GH optimization claims the data hasn't validated

CJC-1295 almost never circulates alone. The protocol that defines its internet presence is the two-peptide stack — CJC-1295 combined with ipamorelin, a ghrelin receptor agonist, on the theory that pairing a GHRH analog with a separate growth hormone secretagogue produces a fuller, more sustained GH pulse than either compound alone. The combination has been a fixture in anti-aging medicine discussions, fitness forums, and biohacking content for the better part of a decade: recommended for lean body composition, sleep quality improvements, faster injury recovery, and general GH-axis optimization framed as an alternative to exogenous growth hormone. When the FDA's 2023 Category 2 designation banned 503A compounding of CJC-1295 and ipamorelin, peptide clinics and optimization communities tracked the prohibition closely. The April 2026 reclassification returned both to compounding-allowed status simultaneously, and within the optimization community the return has been processed in some corners as regulatory endorsement of the stack's clinical claims, or evidence that the compounds had cleared some kind of federal safety review. Neither reading is accurate. What changed in April 2026 is the pharmacy-access category under a specific compounding pathway. What did not change is the evidence base for the body-composition and performance outcomes that make the stack worth prescribing in the first place.

What the data says

human endocrine signal is documented — the performance and body-composition outcomes need their own evidence

The human clinical record for CJC-1295 is real, specific, and narrower than the protocol's reputation. The most frequently cited study enrolled healthy adult volunteers and adults with growth hormone deficiency, demonstrating dose-dependent, sustained increases in GH and IGF-1 concentrations following a single subcutaneous injection — effects persisting for up to six days and maintained across multiple injections over a 28-day period without evidence of desensitization. That endocrine signal is a legitimate finding in human pharmacology. [The PubMed literature on CJC-1295](https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295) extends this foundation: the compound's GHRH-receptor binding, pituitary hormone-release mechanics, and pharmacokinetic extension via albumin binding are documented. [ClinicalTrials.gov records for CJC-1295](https://clinicaltrials.gov/search?term=CJC-1295) reflect registered investigation in this area. What the clinical record does not contain is a controlled human trial measuring whether CJC-1295 — at any dose, in any combination, in healthy adults without GH deficiency — produces superior body composition, meaningful fat loss, enhanced performance recovery, or measurable longevity markers versus placebo. Endocrine markers moved. Whether those markers translate into the outcomes the optimization case assumes is a separate question requiring its own evidence. The GH/IGF-1 axis is also consequential enough that long-term manipulation in healthy adults outside disease contexts warrants that evidence rather than inference from the endocrine signal alone.

Early human — PeptideFactCheck stance

the compounding status changed — the clinical evidence case didn't, and neither did the distinction

CJC-1295 holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. The tier reflects what the published record actually supports. Human pharmacology data documents the endocrine effects. The GH/IGF-1 axis biology is well characterized at the mechanistic level. The Drug Affinity Complex modification solves a real pharmacokinetic problem. What the Early human tier marks is the gap between those documented findings and the performance, body-composition, and longevity outcomes that define the compound's real-world clinical demand — outcomes that have not been measured in the controlled trial that would settle them. The April 2026 reclassification is a compounding-access event, not an evidence event. [The FDA's bulk drug compounding safety framework](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) determines whether a licensed pharmacist may legally prepare a compound for a specific patient under the 503A pathway — a manufacturing and access question that sits entirely apart from clinical validation. Today, June 30, the oral comment window for the FDA's July 23-24 PCAC meeting closes. CJC-1295 is not on that agenda because it was already reclassified. That is a regulatory fact. The controlled human trial measuring the body-composition outcomes that made CJC-1295 famous — and that would close the gap between the endocrine signal and the stack's clinical case — is still missing from the record. Both things are true. The first one got an announcement. The second one didn't change.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.